Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Acquisition of an oncogenic fusion protein is sufficient to globally alter the landscape of miRNA expression to inhibit myogenic differentiation.

Loupe JM, Miller PJ, Crabtree JS, Zabaleta J, Hollenbach AD.

Oncotarget. 2017 Jul 29;8(50):87054-87072. doi: 10.18632/oncotarget.19693. eCollection 2017 Oct 20.


CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion.

Ouhtit A, Abdraboh ME, Hollenbach AD, Zayed H, Raj MHG.

Cell Commun Signal. 2017 Nov 9;15(1):45. doi: 10.1186/s12964-017-0200-3.


Developing cancer therapies - think global.

Hollenbach AD.

Aging (Albany NY). 2016 Nov 16;8(11):2605-2606. doi: 10.18632/aging.101129. No abstract available.


Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects.

Loupe JM, Miller PJ, Bonner BP, Maggi EC, Vijayaraghavan J, Zabaleta J, Taylor CM, Tsien F, Crabtree JS, Hollenbach AD.

Oncotarget. 2016 Sep 27;7(39):62814-62835. doi: 10.18632/oncotarget.11716.


Comparative transcriptomic analysis reveals the oncogenic fusion protein PAX3-FOXO1 globally alters mRNA and miRNA to enhance myoblast invasion.

Loupe JM, Miller PJ, Bonner BP, Maggi EC, Vijayaraghavan J, Crabtree JS, Taylor CM, Zabaleta J, Hollenbach AD.

Oncogenesis. 2016 Jul 25;5(7):e246. doi: 10.1038/oncsis.2016.53.


Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options.

Loupe JM, Miller PJ, Ruffin DR, Stark MW, Hollenbach AD.

Oncogenesis. 2015 Mar 30;4:e145. doi: 10.1038/oncsis.2015.2.


Phosphorylation of PAX3 contributes to melanoma phenotypes by affecting proliferation, invasion, and transformation.

Iyengar AS, Miller PJ, Loupe JM, Hollenbach AD.

Pigment Cell Melanoma Res. 2014 Sep;27(5):846-8. doi: 10.1111/pcmr.12277. Epub 2014 Jun 26. No abstract available.


Identification of CK2 as the kinase that phosphorylates Pax3 at Ser209 in early myogenic differentiation.

Iyengar AS, Loupe JM, Miller PJ, Hollenbach AD.

Biochem Biophys Res Commun. 2012 Nov 9;428(1):24-30. doi: 10.1016/j.bbrc.2012.09.141. Epub 2012 Oct 8.


Survivin is a novel target of CD44-promoted breast tumor invasion.

Abdraboh ME, Gaur RL, Hollenbach AD, Sandquist D, Raj MH, Ouhtit A.

Am J Pathol. 2011 Aug;179(2):555-63. doi: 10.1016/j.ajpath.2011.04.042. Epub 2011 Jun 14. Erratum in: Am J Pathol. 2012 Mar;180(3):1324.


Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.

Dietz KN, Miller PJ, Iyengar AS, Loupe JM, Hollenbach AD.

Int J Biochem Cell Biol. 2011 Jun;43(6):936-45. doi: 10.1016/j.biocel.2011.03.010. Epub 2011 Mar 31.


FOXO1 stimulates ceruloplasmin promoter activity in human hepatoma cells treated with IL-6.

Sidhu A, Miller PJ, Hollenbach AD.

Biochem Biophys Res Commun. 2011 Jan 28;404(4):963-7. doi: 10.1016/j.bbrc.2010.12.089. Epub 2010 Dec 24.


Isolation of putative FOXO1 genomic elements using an improved in vitro technique to isolate genomic regulatory sequences.

Sidhu A, Miller PJ, Hollenbach AD.

Gene. 2010 Jun 15;458(1-2):45-53. doi: 10.1016/j.gene.2010.03.008. Epub 2010 Mar 23.


Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Dietz KN, Miller PJ, Hollenbach AD.

Biochemistry. 2009 Dec 15;48(49):11786-95. doi: 10.1021/bi9012947.


Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts.

Miller PJ, Dietz KN, Hollenbach AD.

Protein Sci. 2008 Nov;17(11):1979-86. doi: 10.1110/ps.035956.108. Epub 2008 Aug 15.


Novel flanking DNA sequences enhance FOXO1a DNA binding affinity but do not alter DNA bending.

Sidhu A, Miller PJ, Johanson KE, Hollenbach AD.

Biochemistry. 2008 Jul 1;47(26):6809-18. doi: 10.1021/bi702495m. Epub 2008 Jun 7.


IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis.

Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, Acharyya S, Rudnicki MA, Hollenbach AD, Guttridge DC.

J Cell Biol. 2008 Feb 25;180(4):787-802. doi: 10.1083/jcb.200707179.


The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis.

Miller PJ, Hollenbach AD.

Biochim Biophys Acta. 2007 Oct;1770(10):1450-8. Epub 2007 Jul 13.


Alternative splicing of Pax3 produces a transcriptionally inactive protein.

Pritchard C, Grosveld G, Hollenbach AD.

Gene. 2003 Feb 13;305(1):61-9.


Thiamine transport in Escherichia coli: the mechanism of inhibition by the sulfhydryl-specific modifier N-ethylmaleimide.

Hollenbach AD, Dickson KA, Washabaugh MW.

Biochim Biophys Acta. 2002 Aug 31;1564(2):421-8.


Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek.

Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R, Grosveld G.

J Cell Sci. 2002 Aug 15;115(Pt 16):3319-30.


The EF-hand calcium-binding protein calmyrin inhibits the transcriptional and DNA-binding activity of Pax3.

Hollenbach AD, McPherson CJ, Lagutina I, Grosveld G.

Biochim Biophys Acta. 2002 Apr 12;1574(3):321-8.


The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx.

Hollenbach AD, Sublett JE, McPherson CJ, Grosveld G.

EMBO J. 1999 Jul 1;18(13):3702-11.

Supplemental Content

Loading ...
Support Center